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Summary
Intracellular malaria parasites require lipids for
growth and replication. They possess a prokary-
otic type II fatty acid synthesis (FAS II) pathway
that localizes to the apicoplast plastid organelle
and is assumed to be necessary for pathogenic
blood stage replication. However, the importance
of FAS II throughout the complex parasite life cycle
remains unknown. We show in a rodent malaria
model that FAS II enzymes localize to the sporozo-
ite and liver stage apicoplast. Targeted deletion of
FabB/F, a critical enzyme in fatty acid synthesis,
did not affect parasite blood stage replication,
mosquito stage development and initial infection
in the liver. This was conﬁrmed by knockout of
FabZ, another critical FAS II enzyme. However, FAS
II-deﬁcient Plasmodium yoelii liver stages failed to
form exo-erythrocytic merozoites, the invasive
stage that ﬁrst initiates blood stage infection. Fur-
thermore, deletion of FabI in the human malaria
parasite Plasmodium falciparum did not show a
reduction in asexual blood stage replication in
vitro. Malaria parasites therefore depend on the
intrinsic FAS II pathway only at one speciﬁc life
cycle transition point, from liver to blood.
Introduction
Malaria parasites are protists belonging to the genus
Plasmodium. They are obligate intracellular parasites that
have two distinct replicating life cycle forms in the mam-
malian host. A massive one-time replication occurs in the
liver after inoculation of sporozoite stages by the bite of an
infected mosquito and results in the production and
release of tens of thousands infectious exo-erythrocytic
merozoites (Prudencio et al., 2006). These merozoites
infect red blood cells and initiate the cyclic replication that
occurs within the blood stream. Blood stage infection
leads to malaria disease with Plasmodium falciparum
alone afflicting more than 500 million people annually
(Snow et al., 2005). Plasmodium replication in red blood
cells produces between 8 and 36 merozoites with each
invasive cycle (Cowman and Crabb, 2006) whereas one-
time replication in the infected hepatocyte produces up
to 40 000 merozoites (Shortt et al., 1951) – an ~2000-
fold difference. It is currently not well understood to
what extent malaria parasites rely on parasitic scavenging
of nutrients versus intrinsic synthesis for growth and
replication.
Lipids are not only essential but are one of the most
abundant components of all organisms and the malaria
parasite needs a plentiful supply of lipids – speciﬁcally
fatty acids for the membrane biogenesis necessary for
invasive stage formation. Plasmodium parasites were ini-
tially assumed to lack the ability to synthesize their own
fatty acids and thus rely on their hosts for lipid scavenging
(Vial and Ancelin, 1992). However, this model came into
question with the discovery of the apicoplast, a relict
plastid organelle of Plasmodium (Kohler et al., 1997).
Plant and algal plastids harbour several key biosynthetic
pathways and the sequencing of the P. falciparum
genome (Gardner et al., 2002) coupled with a detailed
analysis of the proteins of known function that were tar-
geted to the apicoplast (Foth et al., 2003) allowed the
construction of an apicoplast-speciﬁc metabolic map
(Ralph et al., 2004). The apicoplast is of cyanobacterial
origin and one such apicoplast-targeted pathway is
bacterial-like type II fatty acid synthesis (FAS II) (Waller
et al., 1998), a de novo pathway by which Plasmodium
can synthesize fatty acids from derivatives of acetate and
malonate. The fatty acid chain extension step of FAS II is
catalysed by four key enzymes – FabB/F, FabG, FabI and
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cellular microbiologyFabZ and the substrate/product of each reaction is
covalently bound to the acyl carrier protein (ACP) cofactor
(Fig. 1A). Conversely, the mammalian FAS I pathway
utilizes a single enzyme complex and is not present in
Plasmodium based on genome sequence analysis (Bahl
et al., 2003). This is not the case for all apicomplexan
parasites – the genome of Toxoplasma gondii encodes
both FAS I and FAS II enzymes, Cryptosporidium parvum
has FAS I enzyme whereas Theileria annulata does not
harbour either FAS I or FAS II pathways (Mazumdar and
Striepen,2007).DeletionofACPfromT. gondiihasdemon-
strated that apicoplast fatty acid synthesis is essential for
organelle biogenesis and parasite survival in this parasite
(Mazumdar et al., 2006).
The four Plasmodium FAS II enzymes are promising
drug targets because they are of bacterial origin. The
P. falciparum enzymes have been expressed in vitro and
used to reconstitute the elongation module of FAS II
(Sharma et al., 2007). The in vitro system mimicked the in
vivo machinery and known inhibitors of the enzymes of
the elongation module caused the expected accumulation
of intermediates. Thus, Plasmodium possesses a func-
tional FAS II pathway. An early study identiﬁed a Plasmo-
dium FabI and showed that the FabI inhibitor triclosan kills
blood stage parasites (Surolia and Surolia, 2001) and
subsequently a signiﬁcant effort has been undertaken to
develop blood stage FAS II inhibitors to treat malaria
(Gornicki, 2003; Sato and Wilson, 2005; Wiesner and
Seeber, 2005). Although the data suggested that FAS II is
necessary for intra-erythrocytic replication, the expression
of FAS II enzymes has not been studied throughout the
complex infection cycle of the parasite and their impor-
tance in parasite progression throughout the life cycle
remains unknown.
We recently carried out a liver stage transcriptome and
proteome analysis in the model rodent malaria parasite
Plasmodium yoelii and observed that (i) the transcription
of FAS II genes was increased in liver stages when com-
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Fig. 1. Transcript abundance of genes involved in the extension step of type II fatty acid synthesis (FAS II) in Plasmodium yoelii. (A) FAS II
takes place by the condensation of malonyl-ACP with acyl-ACP to form b-ketoacyl-ACP and CO2. This reaction is catalysed by 3-oxoacyl-ACP
synthase I/II (FabB/F, P. yoelii PlasmoDB identiﬁer PY04452). b-Ketoacyl-ACP is reduced by b-ketoacyl-ACP reductase (FabG, PY02416) to
form b-hydroxyacyl-ACP, dehydrated by b-hydroxyacyl-ACP dehydratase (FabZ, PY01586) to form trans-2-enoyl-ACP and ﬁnally reduced by
enoyl-acyl carrier reductase (FabI, PY3846) to acyl-ACP. Successive cycles utilizing these four enzymes add two carbon units per cycle. To
quantitatively determine the transcript levels of genes encoding the enzymes involved in FAS II, RNA was extracted from different stages of
the P. yoelii life cycle, reverse transcribed and used for quantitative PCR. Expression levels were measured in salivary gland sporozoites
(SG SPZ), mixed blood stages (BS), blood stage schizonts (SCH), and in liver stages 12, 24, 40 and 50 h after salivary gland sporozoite
infection (LS-12, LS-24, LS-40 and LS-50 respectively). The expression proﬁle for (B) FabB/F, (C) FabI, (D) FabZ and (E) FabG are shown.
Note that for all four genes, expression is highly upregulated in liver stages.
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in the liver stage proteome; and (iii) hexachlorophene, an
inhibitor of FabG, was able to inhibit liver stage develop-
ment in vitro (Tarun et al., 2008). These results suggested
that FAS II might be important for parasite liver infection.
Here, we show that expression of FAS II only occurs
during the pre-erythrocytic phases of parasite infection
and this allowed unprecedented imaging of the sporozoite
and liver stage apicoplast. Strikingly, gene knockouts of
FabB/F and FabZ, two of the enzymes involved in fatty
acid synthesis demonstrated that FAS II is critical for
normal liver stage development but not for blood stage or
mosquito stage development. Knockout parasites did not
form the ﬁrst generation of invasive merozoites, which are
the critical parasite transition stages to move from the liver
into the blood stream and initiate red blood cell infection.
In addition, gene knockout of FabI from P. falciparum,a
further enzyme involved in FAS II, demonstrated that
FAS II is not critical for P. falciparum blood stage
replication.
Results
The transcript abundance of P. yoelii FAS II genes is
highly upregulated in late liver stage development
We used quantitative RT-PCR (qPCR) to show upregu-
lation of FAS II genes in liver stages because our
previous microarray analysis had indicated preferential
expression in liver stages of P. yoelii (Tarun et al., 2008).
Transcript abundance was analysed in the different
P. yoelii life cycle stages for the four FAS II genes encod-
ing the enzymes involved in fatty acid extension (Fig. 1A).
For all four genes, the level of transcription was highly
increased in pre-erythrocytic stages but the most consis-
tent and substantial expression was seen in late liver
stages when compared with blood stages (Fig. 1B to E).
The qPCR data suggest that FAS II is induced in liver
stages and might thus play an important role for liver
stage development.
P. yoelii FAS II enzymes are expressed in sporozoites
and liver stages and localize to the apicoplast
To further investigate the expression of FAS II during the
parasite life cycle we generated a transgenic P. yoelii line
expressing a myc epitope-tagged FabI under the control
of the endogenous FabI promoter (PyFabI-myc) (Fig. S1).
The quadruple myc tag was fused to the carboxyl (C)-
terminus of FabI and was followed by the 3′ UTR from
Plasmodium berghei dihydrofolate reductase/thymidylate
synthase (DHFR/TS). This expression cassette design
should not alter the stage-speciﬁc expression of FabI as
3′UTRs are involved in mRNA stability, but not regulation
of temporal expression. A similar strategy has previously
been used to study the blood stage expression of
P. falciparum subtilase 1 (Yeoh et al., 2007). PyFabI-myc
allowed for the visualization of FabI expression through-
out the parasite life cycle using indirect immunoﬂuores-
cence assays (IFA) with anti-myc antibodies. FabI-myc
expression was not detectable in the developing mosquito
midgut oocysts and also not in oocyst sporozoites
(Fig. S2). FabI-myc expression was ﬁrst detected in sali-
vary gland sporozoites and localized to a spherical struc-
ture close to the nucleus (Fig. 2A). All P. yoelii FAS II
enzymes including P. yoelii FabI possess a bipartite
leader sequence that predicts import into the apicoplast
(data not shown). As FAS II enzymes localize to the api-
coplast in the apicomplexan T. gondii (Waller et al., 1998),
and FabI from the related apicocomplexan Eimeria tenella
was localized to the apicoplast (Ferguson et al., 2007), we
assume that the FabI-myc expression we detected in
salivary gland sporozoites is apicoplast speciﬁc (Fig. 2A).
This is the ﬁrst published data showing the Plasmodium
sporozoite apicoplast. To analyse FabI expression during
liver stage development, HepG2:CD81 hepatoma cells
(Silvie et al., 2003) were infected with sporozoites from
the PyFabI-myc line. At 7 h post infection (pi) when intra-
cellular sporozoites initiate transformation to trophozoites,
apicoplast morphology as determined by FabI-myc
staining (Fig. 2B), was similar to that of salivary gland
Fig. 2. Expression of type II fatty acid synthesis enzymes involved in extension in salivary gland sporozoites and liver stages of Plasmodium
yoelii. A transgenic P. yoelii parasite (PyFabI-myc) was generated expressing a second copy of FabI fused to a C-terminal quadruple-myc tag
under the control of the FabI endogenous promoter. Expression of FabI in PyFabI-myc in life cycle stages of the parasite was monitored by
IFA using a rabbit anti-myc antibody. Salivary gland sporozoites (A) were isolated from infected Anopheles stephensi mosquitoes, either ﬁxed
for IFA or used to infect HepG2:CD81 cells to study in vitro liver stage development. At increasing time points after infection (B, 7 h, C, 14 h,
D, 24 h, E, 30 h, F, 40 h and G, 48 h) cells were ﬁxed. Using the same methodology, PyFabZ-myc and PyFabG-myc transgenic parasites were
created and expression of FabZ and FabG was monitored at 24 h after infection by IFA (H, PyFabZ and I, PyFabG). The salivary gland
sporozoite was detected with a mouse anti-circumsporozoite protein (CSP) antibody and the liver stage cytoplasm was detected with a mouse
anti-heat shock protein 70 (HSP70) antibody. Fluorescent staining was achieved with Alexa Fluor-conjugated secondary antibodies speciﬁc to
rabbit (Alexa Fluor 488, green) and mouse (Alexa Fluor 594, red) IgG. Nuclear staining was achieved with DAPI. Fluorescent images were
captured using deconvolution microscopy and a merge of captured images is presented on the far right pane (merge). The scale bars equal
5 mm and the white ‘N’ denotes the host cell nucleus. Note: As the liver stage progresses it dramatically increases in size. The results show
that apicoplast-targeted FabI-myc is expressed in the salivary gland sporozoite and the developing liver stage (as are FabZ-myc and
FabG-myc).
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commenced and the apicoplast initiated its division as
indicated by the dumbbell shape (Fig. 2C). By 24 h pi, the
apicoplast had formed a branched lariat-shaped structure
(Fig. 2D), which became more elaborate with advanced
liver stage development at 30 h pi (Fig. 2E). By 40 h pi
(Fig. 2F) the apicoplast had differentiated into hundreds of
intertwining structures that appeared to be segregating.
These results show that FabI expression is initiated in
salivary gland sporozoites and that there is robust
apicoplast-speciﬁc FabI expression throughout liver stage
development. Interestingly, the replication of the liver
stage apicoplast bears striking similarities to that seen in
the apicoplast of developing P. falciparum blood stages
with reference to the changing appearance of the
organelle during schizogony (van Dooren et al., 2005) but
on a much more expansive scale. Strikingly, by 48 h pi
(Fig. 2G), a time point when the P. yoelii liver stage sch-
izont undergoes merozoite formation (Baer et al., 2007),
FabI-myc expression was greatly reduced when com-
pared with 40 h pi (Fig. 2F). This strongly suggests that
FabI expression is downregulated shortly before or during
exo-erythrocytic merozoite formation. Finally, we investi-
gated whether FabI is expressed during asexual blood
stage replication and found that FabI-myc expression was
not detected in blood stages (Fig. 3). To further analyse
FAS II expression, additional parasite lines were created
that expressed epitope-tagged FabZ and FabG (PyFabZ-
myc or PyFabG-myc). Similar expression patterns were
seen throughout the life cycle when compared with FabI-
myc (data not shown), exempliﬁed by the labelling of a
branched lariat-shaped structure at 24 h pi for both
PyFabZ-myc and PyFabG-myc (Fig. 2H and I). Taken as a
whole, the expression data led us to hypothesize that FAS
II is not essential for blood stage development but might
be critical for liver stage development.
P. yoelii FabB/F and FabZ are not essential for blood
stage growth
To test the hypothesis that FAS II is not essential for blood
stage development, we deleted P. yoelii FabB/F, the
enzyme that catalyses the condensation of malonyl-ACP
with the lengthening fatty acyl-ACP formed by FabI
(Fig. 1A) from the parasite genome using a double cross-
over recombination strategy (Menard and Janse, 1997;
Tarun et al., 2007). We decided to delete FabB/F because
it catalyses an essential step in fatty acid synthesis. PCR
genotyping using speciﬁc primers pairs conﬁrmed the
recombination event and the deletion of the FabB/F gene
(Fig. S3) in two cloned knockout parasite lines (fabb/f -)
from two independent transfections. To assay the effect of
FabB/F deletion on blood stage development, mice were
intravenously (iv) injected with 1 ¥ 103 or 1 ¥ 106 fabb/f -
clone 1 parasites and blood stage development was fol-
lowed over time in comparison with wild-type (WT) para-
sites (Fig. 4A and B). There was no signiﬁcant difference
in the growth rate of fabb/f - clone 1 parasites and WT
parasites. Normal clearance of the parasite that is
observed for this non-lethal P. yoelii strain occurred for
both WT and knockout approximately 20 days pi (Fig. 4A
and B). The results demonstrate that the loss of FabB/F
and therefore the loss of FAS II had no deleterious effect
on P. yoelii asexual blood stage replication in vivo.
Fig. 3. Lack of expression of quadruple-myc epitope-tagged FabI in the blood stages of the transgenic P. yoelii parasite PyFabI-myc.
PyFabI-myc was generated to express a second copy of FabI under the control of its endogenous promoter with a C-terminal quadruple-myc
tag. Expression of FabI in PyFabI-myc was monitored by IFA using an anti-myc antibody. Parasite blood stages were detected with antibodies
to (A) the parasitophorous vacuole membrane protein Hep17 and (B) the merozoite-speciﬁc merozoite surface protein 1 (MSP1). Fluorescent
staining was achieved with Alexa Fluor-conjugated secondary antibodies (Alexa Fluor 488, green and Alexa Fluor 594, red) speciﬁc to rabbit
and mouse IgG. Nuclear staining was achieved with DAPI. Differential interference contrast (DIC) and ﬂuorescent images were captured and
processed using deconvolution microscopy and a merge of the captured images is presented on the far right pane (merge). Scale bar is 5 mm.
FabI-myc expression was not detectable in blood stage of parasites.
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normal gametocyte development and male gamete
exﬂagellation (data not shown). To conﬁrm our observa-
tions with fabb/f - parasites we used similar methodologies
to generate a parasite with a deletion in a second synthe-
sis enzyme, FabZ. FabZ catalyses the dehydration of
b-hydroxyacyl-ACP to form trans-2-enoyl-ACP (Fig. 1A).
PCR genotyping conﬁrmed the creation of fabz- parasites
in two cloned knockout lines from independent transfec-
tions (Fig. S3). As for fabb/f - parasites, the deletion of
FabZ had no deleterious effect on the growth of fabz -
blood stage parasites (Fig. 4A and B). A similar blood
stage phenotype from the deletion of a second enzyme in
FAS II adds strength to our hypothesis that FAS II is not
necessary for blood stage replication.
P. yoelii FabB/F and FabZ are necessary for
pre-erythrocytic stage infection
After transmission of either fabb/f - or fabz - to Anopheles
stephensi mosquitoes, we observed normal development
of mosquito midgut oocysts, formation of oocyst sporozoi-
tes and invasion of sporozoites into the salivary glands as
indicated by the enumeration of salivary gland sporozoites
in comparison with WT (Table S1: data for one clone for
each deletion are shown). Therefore, FAS II is not neces-
sary for parasite development in the mosquito. Next, sali-
vary gland sporozoites were injected iv into BALB/c mice.
Mice were injected with 10 000 and 50 000 (n = 8) knock-
out sporozoites or with 10 000 WT sporozoites. Mice were
assayedforbloodstageparasitaemiaeveryotherdayfrom
day 3 post injection (pi) until day 15 by Giemsa-stained
blood smears (Table 1).After 3 days, all mice injected with
WTsporozoitesexhibitedpatentbloodstageparasitaemia.
Strikingly,noneofthemiceinjectedwith10 000and50 000
fabb/f - sporozoites or fabz - sporozoites became blood
stagepatentandthiswastrueforbothclonesofeachofthe
knockouts.These results demonstrate that the lack of FAS
II renders the pre-erythrocytic parasite unable to success-
fully infect the mammalian host.
P. yoelii fabb/f- parasites arrest late in liver stage
development
To further investigate the phenotype of the knockout para-
sites we chose to follow the progression of fabb/f - clone 1
parasites in the liver. BALB/c mice were iv injected with
1 ¥ 106 sporozoites (WT or fabb/f -) and sacriﬁced at dif-
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Fig. 4. Normal blood stage growth of P. yoelii fabb/f
- and fabz
-
parasites and impaired liver stage growth of P. yoelii fabb/f
-
parasites. Double homologous cross-over recombination was used
to delete P. yoelii FabB/F and FabZ to generate P. yoelii fabb/f
-
and fabz
- blood stage parasites respectively. To assess blood
stage growth, one thousand (A) or one million (B) WT, fabb/f
-
clone 1 or fabz
- clone 1 blood stage parasites were injected iv into
6-week-old female SW mice (n = 4 for each group). Subsequently,
blood stage parasitaemia was measured until parasite clearance by
Giemsa-stained blood smear and expressed as a percentage. To
assay liver stage growth, one million WT or fabb/f
- sporozoites
isolated from the salivary glands of infected Anopheles stephensi
mosquitoes were injected into BALB/c mice. The livers were
removed 44 h pi, ﬁxed and then cut into 50 mm sections. Liver
stage parasites were detected using IFA utilizing an antibody to the
parasitophorous vacuole membrane protein Hep17. (C) The area of
the parasite at its widest diameter, based on scanning through the
z plane of the section, was determined and expressed as a
percentage of the total number of parasites in quartiles (for WT,
n = 251 and for fabb/f
-, n = 147). The results show that both
FabB/F and FabZ are not essential for normal blood stage
replication but FabB/F is essential for normal late liver stage
development.
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livers were perfused, removed, sectioned and parasite
load and development was assayed by immunoﬂuores-
cence microscopy. At 12 and 24 h pi fabb/f - liver stages
showed normal development that was indistinguishable
from WT, i.e. they invaded hepatocytes, formed a parasi-
tophorous vacuole (PV), transformed into trophozoites
and initiated schizogony (Fig. 5A and B). However, by
44 h pi the size of the fabb/f - liver stages was signiﬁcantly
less than that of WT (Figs 4C and 6A). Quantiﬁcation of
cell size showed that more than 60% of WT liver stages at
this time point had a maximum area at their widest diam-
eter of > 1500 mm2, whereas more than 90% of the fabb/f -
liver stages were less than 1500 mm2 (Fig. 4C). In addi-
tion, abnormal progression of nuclear division became
apparent. Furthermore, unlike WT, fabb/f - liver stages did
not show merozoite surface protein 1 (MSP1) (Suhrbier
et al., 1989) expression (Fig. 6A and B). At 52 h pi, most
of the WT parasites had formed and released merozoites
or were in the ﬁnal stages of merozoite formation (Fig. 6B)
but, although the fabb/f - liver stages had somewhat
increased in size in comparison with 44 h, there was
still no signiﬁcant expression of MSP1 (Fig. 6B). High-
magniﬁcation differential interference contrast images of
the liver stage parasites (Fig. 6C) showed that at 44 h pi,
cytomere formation, which is due to multiple invaginations
of the liver stage plasma membrane, was occurring in WT
but not in the fabb/f - parasites and at 52 h pi, merozoites
had formed and segregated in WT liver stages but not in
the fabb/f - liver stages (Fig. 6C). The sporozoite infectiv-
ity and liver stage developmental data therefore suggest
that fabb/f - parasites are normal with regard to hepato-
cyte invasion and liver stage development up to a point in
late liver stage schizogony. However, fabb/f - liver stages
do not reach maturity at the time point at which WT liver
stages do and are unable to form infectious merozoites,
explaining the lack of onset of blood stage infection from
the liver. This is an unprecedented phenotype in late liver
stage differentiation caused by the lack of an intrinsic
metabolic pathway.
P. falciparum FabI is not essential for blood stage
growth
To test whether the FAS II pathway might be dispensable
for a clinically relevant human malaria parasite, we
decided to study FabI in the NF54 strain of P. falciparum.
We were able to delete the P. falciparum FabI gene from
blood stage parasites using double homologous cross-
Table 1. P. yoelii FAS II is critical for successful pre-erythrocytic
stage infection.
Parasite genotype
# sporozoites
injected
# mice
injected
# mice blood
stage patent
(day of patency)
Wild type 10 000 10 10 (3)
fabb/f
- clone 1 10 000 18 0 (–)
a
fabb/f
- clone 1 50 000 18 0 (–)
a
fabb/f
- clone 2 10 000 12 0 (–)
a
fabb/f
- clone 2 50 000 12 0 (–)
a
fabz
- clone 1 10 000 8 0 (–)
b
fabz
- clone 1 50 000 8 0 (–)
b
fabz
- clone 2 10 000 4 0 (–)
b
fabz
- clone 2 50 000 4 0 (–)
b
a. Mice injected with 10 000 and 50 000 fabb/f
- sporozoites were
followed for 15 days post injection and never became blood stage
patent.
b. Mice injected with 10 000 and 50 000 fabz
- sporozoites were
followed for 15 days post injection and never became blood stage
patent.
Salivary gland sporozoites were injected intravenously into BALB/c
mice and the mice were assayed for blood stage patency from the
third day after injection.
DAPI  DAPI CSP CSP merge merge
WT  WT
fabb/f- fabb/f-
b a
DAPI  DAPI CSP CSP merge merge
Fig. 5. Development of Plasmodium yoelii WT and fabb/f
- early liver stages in vivo. Salivary gland sporozoites were isolated from Anopheles
stephensi mosquitoes and injected iv into BALB/c mice (one million for both WT and fabb/f
-). The livers were removed at (A) 12 h pi and (B)
24 h pi, ﬁxed and cut into 50 mm sections. Liver stage parasites were detected using an IFA utilizing antibodies to the circumsporozoite protein
(CSP). Fluorescent staining was achieved with Alexa Fluor-conjugated secondary antibodies speciﬁc to rabbit (Alexa Fluor 488, green) and
mouse (Alexa Fluor 594, red) IgG. Nuclear staining was achieved with DAPI. Differential interference contrast and ﬂuorescent images were
captured and processed using deconvolution microscopy and a merge of the captured images is presented on the far right pane (merge). The
scale bars equal 5 mm. Note: As the liver stage progresses there is no difference in the size between the WT and fabb/f
- parasite. The results
suggest that FabB/F is not essential for early liver stage development.
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tive selection. Deletion of the gene was conﬁrmed by
Southern blot analysis of the parental line (data not
shown) and two clonal lines derived from the parental line
(Fig. S4). We then compared the replication of the P. fal-
ciparum fabi- blood stages with that of the WT NF54
strain. We saw no signiﬁcant differences in replication
efficiency between WT and fabi - (Fig. 7 and data not
Fig. 6. Development of Plasmodium yoelii WT and fabb/f
- late liver stages in vivo. Sporozoites were isolated and injected into mice as for
Fig. 5. The livers were removed at (A) 44 h pi and (B) 52 h pi, ﬁxed and cut into 50 mm sections. Liver stage parasites were detected using an
IFA utilizing antibodies to the parasitophorous vacuole membrane protein Hep17 and MSP1. Fluorescent staining was achieved with Alexa
Fluor-conjugated secondary antibodies speciﬁc to rabbit (Alexa Fluor 488, green) and mouse (Alexa Fluor 594, red) IgG. Nuclear staining was
achieved with DAPI. Differential interference contrast (DIC) and ﬂuorescent images were captured and processed using deconvolution
microscopy and a merge of the captured images is presented on the far right pane (merge). The scale bars equal 5 mm. (C) Liver stage DIC
images from (A) and (B) were magniﬁed (dashed box) to show the difference in appearance between WT and fabb/f
- parasites. Note: The
results show that deletion of FabB/F impairs late liver stage development as visualized by the decreased size of the liver stage at 44 and 52 h
pi, the decreased nuclear division, the lack of MSP1 staining and the lack of merozoite differentiation. This suggests that type II fatty acid
synthesis is essential for late liver stage development and the formation of infectious exo-erythrocytic merozoites.
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as for P. yoelii, the FAS II pathway is dispensable for
P. falciparum blood stage growth.
Discussion
Although many metabolic functions have been assigned to
the Plasmodium apicoplast (Ralph et al., 2004), including
FAS II, it is not known if these pathways are essential for
every life cycle stage of the malaria parasite. As the para-
site inhabits both extracellular and intracellular niches and
replicates in the mosquito vector and mammalian host, its
ability to scavenge host nutrients to support replication
presumably varies greatly depending on its environment.
The study presented herein analyses for the ﬁrst time the
importanceofametabolicpathwaythroughouttheparasite
lifecycle.Wedemonstratedthatapicoplast-targetedFASII
is only necessary for Plasmodium late liver stage develop-
ment. Thus, in all other life cycle stages either the parasite
synthesizes fatty acids by a yet unidentiﬁed de novo
pathway or the parasite is able to scavenge all the fatty
acids it requires from the host. Moreover, FAS II is only
needed late in liver stage schizogony. We have previously
shown that the liver stage PV membrane-resident protein
UIS3 interacts with the hepatocyte lipid carrier liver-fatty
acidbindingprotein(Mikolajczaketal.,2007).Itispossible
that this interaction allows for the transfer of lipids from the
hepatocyte cytosol to UIS3 and subsequently to the devel-
oping liver stage and this concept has recently been
buoyed by the fact that P. falciparum UIS3 cocrystallizes
with the lipid phosphatidylethanolamine (Sharma et al.,
2008).Thus,theparasiteliverstagemighthavedeveloped
a means of directly transferring lipids from its host. Never-
theless, host lipids alone are clearly not sufficient for
completion of liver stage development. In the malaria
model under study, no difference was seen in the ﬁrst half
of liver stage development (up to 24 h pi) between WT and
fabb/f - parasites and it was only after 24 h that the fabb/f -
liver stages showed growth retardation, accompanied by
lack of cytomere formation and subsequent merozoite
differentiation. Thus, during the complete P. yoelii life
cycle, FAS II is required only for the ﬁnal stages of parasite
transition from its ﬁrst site of infection in the liver to the
blood. We do not currently know why FAS II is only neces-
sary for late liver stage development. It is possible that the
sheer amount of membrane biogenesis required for the
formation of tens of thousands of merozoites (Baer et al.,
2007)cannotbemetbyhostlipidscavengingandthusalso
reliesonparasite-derivedfattyacidsynthesistogiveaﬁnal
boost to the formation of the merozoite membrane phos-
pholipid bilayers. Alternatively, FAS II could be necessary
to provide a particular fatty acid that is necessary for late
liver stage development. In the sleeping sickness parasite,
Trypanosoma brucei, the bloodstream form evades the
host’s immune response by expressing continually switch-
ing variant surface glycoprotein molecules (Donelson,
2003). The variant surface glycoprotein is attached to the
plasma membrane by a glycosylphosphatidylinositol (GPI)
anchor whose fatty acids are exclusively myristate (Fergu-
son and Cross, 1984). The continuous supply of myristate
cannot be met by the bloodstream and T. brucei has a
unique de novo fatty acid synthesis pathway to supply its
myristate needs (Lee et al., 2006). Perhaps Plasmodium
FASIIisfulﬁllingasimilarneedbysupplyingparticularfatty
acids necessary for late liver stage schizogony that the
parasite cannot obtain from its host. It is of interest to note
that MSP1 is a GPI-anchored protein (Gerold et al., 1996).
However, we currently do not know if GPI biosynthesis is
abrogatedinFASII-deﬁcientliverstages.Notwithstanding,
we observed lack of MSP1 in liver stages of FAS II knock-
out parasites, suggesting that MSP1 could play an essen-
tial role in the formation of exo-erythrocytic merozoites.
Our data show that some FAS II enzymes are initially
expressed in the salivary gland sporozoite based on both
epitope tagging of FabI and our qRT-PCR data. This also
revealed a high transcript abundance for FabI and FabB/F
in salivary gland sporozoites although this was not the
case for FabG and FabZ. We currently do not understand
the functional signiﬁcance of these increases; neverthe-
less, the pathway is clearly not necessary in this life cycle
stage as both fabb/f - and fabz - sporozoites infected the
mosquito salivary glands and were able to initiate liver
stage infection. Previously, it was shown that depletion of
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Fig. 7. Normal blood stage growth of P. falciparum fabi
- parasites.
Double homologous cross-over recombination was used to delete
P. falciparum FabI and generate P. falciparum fabi
- blood stage
parasites. To assess blood stage growth, parasite cultures of both
the WT NF54 and the fabi
- clone E6 containing mainly ring stages
were synchronized twice within 4 h using sorbitol (Lambros and
Vanderberg, 1979). Parasite density was determined and the
culture was diluted to 0.8% parasitaemia, 5% haematocrit. Cultures
were maintained under an atmosphere of reduced oxygen at 37°C
and medium was refreshed every 24 h. Growth, based on
percentage parasitaemia, was monitored by Giemsa-stained thin
blood smears every 24 h for 5 days. The experiment was carried
out in triplicate and mean and standard deviations are shown. The
results show that there are no signiﬁcant differences in the growth
of the two parasite lines.
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initially expressed in sporozoites and localize to the PV
membrane during liver stage development, as well as the
sporozoite proteins P52 and P36 (van Dijk et al., 2005;
Ishino et al., 2005; Labaied et al., 2007), and the sporo-
zoite asparagine-rich protein 1 (Aly et al., 2008), cause
arrest early in liver stage development. However, deple-
tion of these proteins, as shown here for FabB/F and
FabZ, does also not affect salivary gland sporozoite matu-
ration. Furthermore, the liver stage phenotype for fabb/f -
parasites is unique, when compared with the above as the
parasites do not arrest early in liver stage development
but grow substantially and undergo schizogony.At 52 h pi,
the fabb/f - liver stages still seemed viable, based on the
presence of an intact PV membrane (visualized by Hep17
expression). Nevertheless, liver stage development is
not completed and the parasites might be cleared by
host defence mechanisms although this requires further
investigation.
Our studies have also shown that FAS II is not neces-
sary for either the mosquito stage or blood stage of the
P. yoelii life cycle. It is currently not known how the para-
site utilizes host lipids whilst developing on the mosquito
midgut but it is well documented that host serum fatty
acids are utilized by parasite blood stages for growth
(Krishnegowda and Gowda, 2003; Mi-Ichi et al., 2006).
Our results appear to contradict previous work demon-
strating that triclosan, an inhibitor of FabI (McMurry et al.,
1998), is able to kill cultured P. falciparum blood stages
and in vivo rodent blood stage infections of P. berghei
(Surolia and Surolia, 2001). Others have also concluded
that FAS II inhibitors are directly interacting with their
apicoplast targets in Plasmodium blood stages (Surolia
et al., 2004; Jones et al., 2005; Tasdemir et al., 2006;
Goodman et al., 2007), thereby inhibiting parasite
growth. However, it is possible that the FAS II inhibitors
used are having off target effects on parasite growth.
This has previously been shown in T. brucei, where it
was concluded that triclosan killing may be due to a non-
speciﬁc perturbation of subcellular membrane structure
leading to dysfunction in sensitive membrane-resident
biochemical pathways (Paul et al., 2004). Furthermore,
studies of the effect of triclosan on several microorgan-
isms have concluded that the interaction of triclosan with
the bacterial cell is complex and its lethality cannot be
explained solely by the inhibition of metabolic pathways
such as FAS II (Escalada et al., 2005). Thus, triclosan
could be killing P. falciparum blood stages by inhibiting a
vital process other than FAS II. It has recently been
shown based on transcriptional data obtained form
malaria patient isolates, that there appears to be three
distinct P. falciparum blood stage physiological states
(Daily et al., 2007). These three states closely resemble
(i) active growth; (ii) starvation; and (iii) environmental
stress. In the starvation state, the authors noted an
upregulation of FAS II genes when compared with active
growth. These data suggest that under active glycolytic
growth conditions, which were similar to the P. falciparum
3D7 growth conditions in vitro for which transcriptome
proﬁles have been previously published (Bozdech et al.,
2003; Le Roch et al., 2003), FAS II is not signiﬁcantly
involved in blood stage replication.
This study has concentrated on the effect of FAS II
depletion on liver stage development in the rodent malaria
parasite P. yoelii. However, we have also shown that the
deletion of FabI from the human malaria parasite, P. fal-
ciparum has no apparent effect on blood stage replication
when compared with WT parasites. This result, which
converges on the results we obtained for the deletions of
P. yoelii FabB/F and FabZ, demonstrates that FAS II is not
required in blood stages. Future work might determine
whether deletion of FabI affects P. falciparum sporozoite
infectivity in humans; however, this requires a clinical
investigation. Collectively, the data suggest that the meta-
bolic pathways present in the Plasmodium apicoplast are
not always necessary to support parasite progression
through the speciﬁc parts of the life cycle. Thus, this
unique organelle is likely to perform its critical metabolic
functions at only certain time points during the Plasmo-
dium life cycle and the functions it performs will be directly
related to the needs the parasite cannot fulﬁl by nutrient
uptake from the host. The Plasmodium apicoplast, as well
as being the centre for FAS II, is also thought to harbour
the only pyruvate dehydrogenase complex the parasite
possesses (Foth et al., 2005). It is possible that pyruvate
dehydrogenase is solely required by the apicoplast for the
formation of acetyl CoA which is subsequently utilized by
FAS II. Further studies are needed to address this issue.
Although our ﬁndings concerning liver stage develop-
ment were generated with the rodent malaria parasite
P. yoelii, the high conservation of FAS II among Plasmo-
dium species (Carlton et al., 2002) suggests that FAS II is
also essential for P. falciparum liver stage development.
This might have consequences for the direction of anti-
malaria FAS II inhibitor drug development. Rather than
concentrating on the P. falciparum blood stage, research
into FAS II inhibitors should concentrate on their efficacy
against the initial, clinically silent liver stage of infection.
This might signiﬁcantly contribute to the goal of eradicat-
ing malaria.
Experimental procedures
Experimental animals
Six- to eight-week-old female Swiss Webster (SW) mice and
female BALB/c mice were purchased from Harlan (Indianapolis,
IN). Animal handling was conducted according to institutional
animal care and use committee-approved protocols.
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Plasmodium yoelii (17XNL) liver stage-infected hepatocytes were
isolated at four time points post infection from infected mice: 12 h
(LS-12), 24 h (LS-24), 40 h (LS-40) and 50 h (LS-50). Sporozoi-
tes were isolated from mosquito salivary glands at day 15 after
infectious blood meal. Contaminating mosquito tissue was
removed from sporozoite preparation by passing the extract over
a DEAE cellulose column. For the preparation of parasites in the
mixed blood stages, blood was harvested from infected SW mice
when parasitaemia was at 5–10%. Lymphocytes were removed
by passing the infected blood through a sephadex column. Puri-
ﬁed blood stage schizonts were prepared from Nycodenz puriﬁ-
cation of P. yoelii infected blood cultured for 12 h.
Quantitative real-time PCR
Total RNA from each sample was extracted using Trizol
(Invitrogen) and DNase treated using Turbo-DNA free (Ambion).
Total RNA was then subjected to two rounds of linear ampliﬁ-
cation using the Amino Allyl Message Amp II aRNA Ampliﬁca-
tion Kit (Ambion) according to manufacturer’s directions. First-
strand cDNA was synthesized from 500 ng of ampliﬁed RNA
(aRNA) using the Superscript III Platinum RT kit (Invitrogen).
The resulting cDNA was diluted 1:5 with nuclease-free water.
Primers (Table S2) were designed using Primer Express v3.0
(Applied Biosystems). Designs were based on the mRNA
sequence of the genes available at PlasmoDB. Amplicons were
set to be between 100 and 200 bp. Real-time PCR analysis
was performed on ABI prism 7300 Sequence Detection
Systems using the SYBR Green PCR Master Mix (Applied Bio-
systems). The PCR reaction consisted of 12.5 ml of SYBR
Green PCR Master Mix, 20 pmole of forward and reverse
primers and 5 ml of diluted cDNA in a total volume of 25 ml. PCR
cycling conditions were performed using the default conditions
of the ABI Prism 7300 SDS Software.
Quantiﬁcation of gene expression was done using the Relative
Standard Curve Method (Applied Biosystems bulletin). The stan-
dard is prepared from a mixture of aRNA (salivary gland sporo-
zoites, blood stages and liver stages) in a 1:1:1 ratio. First-strand
cDNA is prepared from the standard and dilutions of 1:1, 1:5,
1:10, 1:20 and 1:50 of the resulting cDNA was used as templates
for real-time PCR for each primer pair. The relative quantity of
gene in the cDNAs from the seven aRNAsamples (salivary gland
sporozoites, LS-12, LS-24, LS-40, LS-50, mixed blood stages
and blood stage schizonts) is interpolated from the correspond-
ing standard curve. Expression of the FAS II genes was normal-
ized to the expression of three housekeeping genes: P. yoelii
18S, 14-3-3 protein (PY01841) and the mitochondrial EF-TU
gene (PY06134) in each cDNA sample. Normalized quantity of
each target gene is expressed as the ratio of the relative amount
of target gene over the average quantity of the three housekeep-
ing genes.
Generation of P. yoelii transgenic parasites expressing
FabI-myc, FabZ-myc and FabG-myc
To epitope tag FabI, a quadruple (4¥) myc tag sequence followed
by a stop codon was introduced into the b3D.DT^H.^D vector
(Catalog # MRA-80 in the MR4 Malaria Research and Refer-
ence Reagent Resource Center; http://www.mr4.org). A graphic
representation of the construction of the plasmid and its subse-
quent transfection into P. yoelii blood stages is given in Fig. S1.
Approximately one kilobase pairs (kb) of the 3′ untranslated
region of the P. berghei DHFR/TS gene was added to the
C-terminus of the 4¥ myc tag to ensure stability of the recombi-
nant messenger RNA. The P. yoelii FabI gene (PY03846), includ-
ing approximately 1 kb of sequence upstream of the start codon
was ampliﬁed from P. yoelii 17XNL genomic DNA and cloned in
frame (without the stop codon) and upstream of the 4¥ myc tag.
The resulting plasmid was linearized with BsaI for integration into
P. yoelii 17XNL blood stage schizonts using standard procedures
(Labaied et al., 2007). Integration of the plasmid to create
PyFabI-myc gave rise to a parasite line that expressed two
copies of FabI, both with the endogenous promoter and one
containing the 4¥ myc epitope tag. Oligonucleotide primers used
are in Table S2. A similar strategy was used to generate PyFabZ-
myc and PyFabG-myc.
In vitro analysis of PyFabI-myc, PyFabG-myc and
PyFabZ-myc liver stages
In vitro assays were conducted using the human hepatoma cell
line HepG2 expressing the tetraspanin CD81 (HepG2:CD81) cul-
tured in Dulbecco’s modiﬁed Eagle’s medium with 10% fetal calf
serum at 37°C and 5% CO2. Infections were done by adding
5 ¥ 10
4 sporozoites to individual chambers of an 8 well chamber
slide (Laboratory-Tek Permanox eight-well chamber slide; Nalge
Nunc International, Rochester, NY) which had been seeded with
10
5 subconﬂuent HepG2:CD81 cells the previous day. The slide
was then centrifuged at 500 g for 2.5 min to aid sporozoite infec-
tion. Sporozoites which had failed to invade cells were removed
after 2 h and the media were replaced. For the liver stage devel-
opment assay, infections were maintained for various time
periods after the addition of salivary gland sporozoites. Subse-
quently the infected cells were ﬁxed in 4% paraformaldehyde in
phosphate buffered saline (PBS) for 10 min, then blocked and
permeabilized in PBS with 2% bovine serum albumin and 0.2%
Triton-X 100 (PBS/BSA/Triton) for IFA. IFA was carried out in
PBS/BSA/Triton. The double staining was performed using a
mouse monoclonal anti-P. berghei HSP70 primary antibody (Tsuji
et al., 1994), a parasite cytoplasmic marker and a rabbit poly-
clonal anti-myc antibody (Santa Cruz Biotechnology, Santa Cruz,
CA), which recognizes the recombinant apicoplast-expressed
FabI-myc. Fluorescent staining was achieved with Alexa
Fluor-conjugated secondary antibodies (Invitrogen Corporation,
Carlsbad, CA) speciﬁc to rabbit (Alexa Fluor 488, green) and
mouse (Alexa Fluor 594, red) IgG. Cells were stained with 4′,6′-
diamidino-2-phenylindole (DAPI) to visualize the DNA and
mounted with FluoroGuard anti-fade reagent (Bio-Rad, Hercules,
CA). Preparations were analysed using a ﬂuorescence inverted
microscope (Eclipse TE2000-E; Nikon), and images were
acquired using Olympus 1 ¥ 70 Delta Vision deconvolution
microscopy.
Generation of P. yoelii fabb/f- and fabz - parasites
For the targeted deletion of the FabB/F (PY04452) and FabZ
(PY01586) genomic loci, two DNA fragments containing approxi-
mately 0.8 kb of the 5′UTR and 3′UTR of the gene were ampliﬁed
516 A. M. Vaughan et al.
© 2008 The Authors
Journal compilation © 2008 Blackwell Publishing Ltd, Cellular Microbiology, 11, 506–520using P. yoelii 17XNL genomic DNA as a template. The two
fragments were cloned into the b3D.DT^H.^D targeting vector
between the T. gondii DHFR/TS gene, which allows selection of
recombination events with pyrimethamine. The plasmid was
transfected into P. yoelii 17XNL blood stage schizonts using
standard procedures (Labaied et al., 2007). Two independent
clones of fabb/f
- and fabz
- parasites were obtained by limited
dilution of parentals from independent transfection experiments.
Agraphic representation of the construction of the plasmid and its
subsequent transfection into P. yoelii blood stages is given in
Fig. 3 and the primers used in Table S2.
Phenotypic analysis of blood stage P. yoelii fabb/f- and
fabz- parasites
To assay growth of non-lethal P. yoelii 17XNL WT, fabb/f
- and
fabz - blood stages, blood was removed from infected SW mice
when parasitaemia was between 0.5% and 1.5%. The blood was
diluted in RPMI-1640 media (HyClone, Logan, UT) so that 100 ml
contained either 10
3 or 10
6 parasites. SW mice (four in each
group) were then injected iv with 103 or 106 parasites (WT or
fabb/f
-). Percentage parasitaemia was followed as often as daily
until clearance, by assay of Giemsa-stained blood smear.
Phenotypic analysis of P. yoelii fabb/f- and fabz -
parasites in the mosquito
Anopheles stephensi mosquitoes were infected with P. yoelii WT,
fabb/f
- or fabz - parasites by blood feeding for 6 min on the ﬁrst
and second day using infected SW mice and subsequently main-
tained under a cycle of 12.5 h light/11.5 h dark and 70% humidity
at 24.5°C. Gametocyte exﬂagellation capacity was evaluated
microscopically before mosquito blood meal. Infected mosqui-
toes were dissected (at least 20 mosquitoes for each dissection)
at days 10 and 14 (after the ﬁrst infectious blood meal) to deter-
mine the presence of midgut oocyst sporozoites and the numbers
of salivary gland sporozoites respectively.
In vivo analysis of P. yoelii fabb/f- liver stage
development
To analyse in vivo sporozoite infection and liver stage develop-
ment, BALB/c mice were injected iv with 10
6 WT or fabb/f
-
sporozoites. For each parasite population, the livers were har-
vested from euthanized mice at several time points post infection
(12, 24, 44 and 52 h). Livers were perfused with PBS, washed
extensively with PBS and then ﬁxed in 4% paraformaldehyde.
Liver lobes were cut into 50 mm sections using a Vibratome
apparatus (Ted Pella Inc., Redding, CA). For IFA, sections were
permeabilized in Tris buffered saline (TBS) containing 3% H2O2
and 0.25% Triton X-100 for 30 min at room temperature. Sections
were then blocked in TBS containing 5% dried milk (TBS-M) at
least 1 h and incubated with primary antibody in TBS-M at 4°C
overnight. Primary antibodies used were mouse monoclonal
anti-circumsporozoite protein, mouse monoclonal anti-Hep17
(Charoenvit et al., 1995) and rabbit polyclonal anti-MSP1. After
washing in TBS, secondary antibody was added in TBS-M for 2 h
at room temperature in a similar manner as above. After further
washing, the section was incubated in 0.06% KMnO4 for 10 min
to quench background ﬂuorescence. The section was then
washed with TBS and cells were stained with DAPI to visualize
the DNA and mounted with FluoroGuard anti-fade reagent
(Bio-Rad, Hercules, CA). Preparations were analysed as above
for ﬂuorescence with the addition of acquisition of a differential
interference contrast image.
Comparison of WT and fabb/f - liver stage growth
To compare the sizes of parasite liver stages at 44 h pi, liver
sections labelled with Hep17 (see above) were sequentially
scanned using Nikon ﬂuorescence microscopy. The greatest
diameter for each liver stage detected was determined by adjust-
ing the z plane of the liver section and the area of the parasite
was subsequently determined. For the WT, 251 liver stages were
assayed and for the fabb/f
-, 147.All parasite segments were less
than 3000 mm
2 and the total numbers of parasites were divided
into quartiles by area.
Generation of P. falciparum fabi - parasites
Targeting sequences 5′ and 3′ to P. falciparum FabI (PFF0730c)
were cloned into plasmid pCC1 to facilitate positive–negative
selection (Maier et al., 2006) (Fig. S4). Restriction sites in the
multiple cloning site were SacII/SpeI for the 5′ ﬂank and AvrII/
EcoRI for the 3′ ﬂank. Sequencing was performed to conﬁrm
inserts and primers used are detailed in Table S2. Plasmid DNA
was extracted by maxi prep kit (Qiagen). The NF54 line P. falci-
parum parasites were synchronized at ring stage with sorbitol
2 days prior to transfection. On the following day trophozoites
were selected for WT cytoadherence properties by incubation in
RPMI plus Gelofusine (Braun). Transfection of P. falciparum ring
stages with 100 mg of DNA was performed by electroporation at
0.31 kV and 950 mF with a Bio-Rad Gene Pulser (Bio-Rad, La
Jolla, CA). Cultures were placed on the positive selection drug
WR99210 (Jacobus Pharmaceuticals, Princeton, NJ) 6 h post
transfection and maintained as described (Crabb et al., 2004).
This was followed by negative selection against the cytosine
deaminase/uracil phosphoribosyl transferase gene product with
5-ﬂuorocytosine in order to obtain a parental line with double
cross-over homologous recombination, which results in speciﬁc
FabI gene deletion.
Two individual clones with a FabI deletion were isolated (E6
and G8) and genotypic analysis was conﬁrmed by Southern Blot
(Fig. S4). Genomic DNA from WT NF54 and knockout lines was
digested for 2–16 h with the following enzymes: 5′ test: KpnI/BglII
and 3′ test: BglII/BamHI. Digested DNA was run on a 1% TAE
agarose gel at 15 V for 18 h and transferred to Hybond-N mem-
brane (Amersham) overnight at room temperature, UV cross-
linked and pre-hybridized with herring sperm DNA for 2.5 h. A
digoxygenin-labelled probe was prepared by PCR per supplier
protocol (Roche) using the cloning primers. Hybridization was
carried out for 18 h at 55°C. The blot was exposed to ﬁlm for
10–60 min and developed per standard protocol.
Assessment of P. falciparum growth
Parasite cultures of both the WT NF54 and the fabi
- clone E6
containing mainly ring stages were synchronized twice within 4 h
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was determined and the culture was diluted to 0.8% parasi-
taemia, 5% haematocrit. Cultures were maintained under an
atmosphere of reduced oxygen at 37°C and medium was
refreshed every 24 h. Growth was monitored by Giemsa-stained
thin blood smears every 24 h and for each determination of
percentage parasitaemia, the number of infected erythrocytes
per at least 2000 erythrocytes was recorded.
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Supporting Information
Additional Supporting Information may be found in the online
version of this article:
Fig. S1. Integration of a second copy of FabI fused to a qua-
druple myc tag into the P. yoelii genome (PyFabI-myc). A. The
FabI gene, including 1 kb upstream of the start methionine and
up to but not including the stop codon was ampliﬁed and ligated
upstream of the quadruple myc tag (4¥ myc) in the 4¥ myc tag
integration vector. Following linearization of the vector with BsaI,
the construct was transfected into P. yoelii blood stage schizonts
which were subsequently injected into mice. The vector contains
the T. gondii DHFR/TS mutated gene as a pyrimethamine select-
able marker (TgDHFR) and integrants were selected for by
pyrimethamine treatment. B. Ethidium bromide-stained agarose
gel showing the integration of the FabI-myc vector into the
P. yoelii genome. Only PyFabI-myc is positive for this test
(‘int test’), whereas, as expected, both PyFabI-myc and wild-type
parasite genomic DNA is positive for the FabI-speciﬁc open
reading frame test (‘ORF test’). Note that the selected parasites
have two copies of FabI, the wild-type copy and the 4¥ myc
tagged copy, both with their endogenous promoter. PyFabI-myc
should express a second copy of FabI with a myc epitope and the
expression of the tagged protein should mimic that of the endo-
genous copy. The same integration strategy was used to gener-
ate PyFabG-myc and PyFabZ-myc..
Fig. S2. Lack of expression of quadruple-myc epitope-tagged
FabI in the (A) developing midgut oocyst sporozoites and (B) free
midgut sporozoites of the transgenic P. yoelii parasite PyFabI-
myc. PyFabI-myc was generated to express a second copy of
FabI under the control of its endogenous promoter with a
C-terminal quadruple-myc tag. Expression of FabI in PyFabI-myc
was monitored by immunoﬂuorescence assay (IFA) using a rabbit
anti-myc antibody. The oocyst and midgut sporozoites were
detected with a mouse anti-circumsporozoite protein (CSP) anti-
body. Fluorescent staining was achieved with Alexa Fluorconju-
gated secondary antibodies (Alexa Fluor 488, green and Alexa
Fluor 594, red) speciﬁc to rabbit and mouse IgG. Nuclear staining
was achieved with 4′,6-diamidino-2-phenylindole (DAPI). Differ-
ential interference contrast (DIC) and ﬂuorescent images were
captured and processed using deconvolution microscopy and a
merge of the captured images is presented on the far right pane
(merge). Scale bar is 5 mm. FabI-myc expression was not detect-
able during sporozoite development in the mosquito.
Fig. S3. Successful deletion of P. yoelii FabB/F and FabZ by
double cross-over homologous recombination to generate
P. yoelii fabb/f
- and fabz
- knockout parasites. (A) DNA frag-
ments of approximately 800 base pairs spanning the 5′ and 3′
UTR of the FabB/F gene (PY04452) and FabZ gene (PY01586)
were ligated into the b3D.DT^H.^D vector. The vector contains
the T. gondii DHFR/TS mutated gene as a pyrimethamine select-
able marker (TgDHFR). The vector was linearized with KpnI and
SacII and transfected into P. yoelii blood stage schizonts which
were then injected into SW mice. Double cross-over homologous
recombination was selected for with pyrimethamine and con-
ﬁrmed by a positive PCR result using the primer sets ‘test 1’ and
‘test 2’ and a negative PCR result for the deleted gene (‘wt test’).
(B) Ethidium bromide-stained agarose gel showing PCR products
from the ampliﬁcation of parasite genomic DNA from two clonal
populations (clone 1 and clone 2) of the FabB/F gene deletion
and wild-type (wt). (C) Similar to (D) but for the FabZ gene. The
PCR results demonstrate the successful deletion of the genes
because the ‘test 1’ and ‘test 2’ primer sets are positive only for
the knockout population. Similarly, the wild-type test (‘wt test’) is
positive only for the wild-type population. The result shows that
the FabB/F and FabZ genes have been successfully deleted from
blood stage P. yoelii parasites.
Fig. S4. Deletion of FabI in P. falciparum. (A) Targeting
sequences 5′ and 3′ to P. falciparum FabI (PFF0730c) were
cloned into plasmid pCC1 to facilitate positive-negative selection
(Maier et al., 2006). Restriction sites in the multiple cloning site
were SacII/SpeI for the 5′ ﬂank and AvrII/EcoRI for the 3′ ﬂank.
Genomic DNA from WT NF54 and knockout lines (clones E6 and
G8) were assayed by Southern Blot and using the 5′ and 3′ ﬂanks
as probes and the expected restriction fragments resulting from
enzymatic digestion of the WTloci and KO loci are shown. (B)The
fragments recognized by the 5′ probe of KpnI/BglII restricted DNA
are 6.1 kb for the WT locus and 1.3 kb for the KO locus. (C) The
fragments recognized by the 3′ probe of BgllI/BamHI restricted
DNA are 4.6 kb for the WT locus and 4.1 kb for the KO locus.
Table S1. P. yoelii fabb/f
- and fabz - parasites develop normally
in the mosquito.
Table S2. Oligonucleotide primers used in the study.
Please note: Wiley-Blackwell are not responsible for the content
or functionality of any supporting materials supplied by the
authors. Any queries (other than missing material) should be
directed to the corresponding author for the article.
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